J. Grigorieva

I. Floriani, A. Bachi, H. Roder, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer

J. Berlin, Y. Shyr, E. Chan, 2014, Cancer medicine.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

R. Gray, R. Caprioli, P. Massion, 2007, Journal of the National Cancer Institute.

United States Patent Röder

J. Grigorieva, 2017 .

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

D. Carbone, L. Seymour, M. Tsao, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma

R. Sullivan, P. Ascierto, R. Halaban, 2017, Cancer Immunology Research.

VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

E. Smit, A. Dingemans, H. Roder, 2012, British Journal of Cancer.

A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer

M. Socinski, A. Peterman, T. Stinchcombe, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A proposal for score assignment to characterize biological processes from mass spectral analysis of serum

H. Pass, J. Weber, H. Roder, 2020, Clinical mass spectrometry.

Abstracts from the 4th ImmunoTherapy of Cancer Conference

R. Rees, F. Regnier, A. Trautmann, 2017, Journal of Immunotherapy for Cancer.

In situ mass spectrometry of autoimmune liver diseases

R. Caprioli, M. Gershwin, C. Bowlus, 2011, Cellular and Molecular Immunology.

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy

C. Maggioni, H. Roder, J. Grigorieva, 2016, British Journal of Cancer.

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

A. Argento, R. C. McDonald, J. Grigorieva, 2020, Current medical research and opinion.

Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based Test

D. Mahalingam, K. Attwood, R. Iyer, 2021, Cancers.

Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).

S. Barni, V. Torri, S. Novello, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients

R. Caprioli, D. Carbone, C. Chung, 2010, Cancer Epidemiology, Biomarkers & Prevention.